Equity Issuances

LITHIUM AMERICAS CORP. issued 18,268,687 Common Shares of warrant to United States Department of Energy for $0.01 per share exercise price.

“The A&R Company Warrant is to purchase up to 18,268,687 Common Shares, which is equal to 5% of the Company's total outstanding shares as of the Issuance Date, with an exercise price of $0.01 per share, exercisable for ten years from the date of issuance of the A&R Company Warrant, subject to customary anti-dilution adjustments and other terms set forth in the A&R Company Warrant.”

EQT Infrastructure Co LLC issued 394,158 of common stock to EQT Holdings AB for contribution of ownership interests in ju:niz Energy GmbH.

“the Company issued to EQT Holdings AB, an indirect subsidiary of EQT AB, a total of approximately 394,158 Class E Shares of the Company (the “Class E Shares”), valued at $25.00 per Class E Share, in exchange for the contribution to the Company of ownership interests in ju:niz Energy GmbH, a battery energy storage system developer and operator.”

EQT Infrastructure Co LLC issued 7,147,645 of common stock to third-party investors for $178,691,137.

“As of February 1, 2026, EQT Infrastructure Company LLC (the “Company”) sold unregistered shares (the “Investor Shares”) of the Company to third-party investors for cash for aggregate consideration of approximately $178,691,137, at a price per Investor Share of $25.00.”

Audax Private Credit Fund, LLC issued 2,017,095.383 of common stock to accredited investors for $50.5 million.

“On January 2, 2026, Audax Private Credit Fund, LLC (the “ Fund ”) sold limited liability company interest (the “ Shares ”). The purchase price per share and number of Shares issued was finalized on January 30, 2026. The purchase price per share was equal to $25.036. The following table details the Shares sold: Date of Issuance Common Shares Issued Total Consideration (in millions) January 2, 2026 2,017,095.383 $ 50.5”

Remora Capital Corp issued 627,254.509 shares of common stock of common stock for $6,260,000.

“On February 2, 2026, Remora Capital Corporation (the “Company”) issued 627,254.509 shares of common stock (the “Shares”) of the Company for an aggregate offering price of $6,260,000.”

CNL Strategic Residential Credit, Inc. issued 14,200 shares of common stock for $25.00 per share.

“On January 29, 2026, the Company held an initial closing for its Private Offering and issued 966,038 shares of Class E common stock and 14,200 shares of Class FA common stock at a purchase price of $25.00 per each share for aggregate gross offering proceeds of approximately $24.5 million.”

CNL Strategic Residential Credit, Inc. issued 966,038 shares of common stock to the Advisor, Balbec Capital Holdings, L.P. for $25.00 per share.

“On January 29, 2026, the Company held an initial closing for its Private Offering and issued 966,038 shares of Class E common stock and 14,200 shares of Class FA common stock at a purchase price of $25.00 per each share for aggregate gross offering proceeds of approximately $24.5 million.”

K2 Capital Acquisition Corp issued 326,876 private units of unit to K2 Capital Sponsor LLC for $8.00 per Private Unit.

“the Company consummated the private placement (“Private Placement”) with K2 Capital Sponsor LLC, the Company’s sponsor (the “Sponsor”), of 326,876 private units (the “Private Units”) at a price of $8.00 per Private Unit, generating total proceeds of $2,615,000”

M Evo Global Acquisition Corp II issued 8,000,000 private placement warrants of warrant to the Sponsor, CCM and Clear Street, LLC for $1.00 per Private Warrant.

“Simultaneously with the closing of the IPO, the Company completed the private sale of an aggregate of 8,000,000 private placement warrants (the “ Private Warrants ”), at a purchase price of $1.00 per Private Warrant, of which 5,000,000 Private Warrants were sold to the Sponsor and 3,000,000 Private Warrants were sold to CCM and Clear Street, LLC (2,850,000 and 150,000, respectively) generating gross proceeds to the Company of $8,000,000.”

Muzero Acquisition Corp issued 486,875 units (the Private Placement Units) of unit to Muzero Acquisition Sponsors LLC (the Sponsor) and BTIG, LLC for $10.00 per Unit.

“the Company completed the private placement of an aggregate of 486,875 units (the “ Private Placement Units ”) to the Sponsor and BTIG, LLC, the representative of the underwriters, at $10.00 per Unit”

RIDGEFIELD ACQUISITION CORP issued common stock.

“On January 15, 2026, Ridgefield Acquisition Corp. (the "Company") filed a Certificate of Amendment to its Articles of Incorporation with the Secretary of State of the State of Nevada, which became effective upon filing at 6:00 p.m. Eastern Time (the "Reverse Split Effective Time").”

LEXICON PHARMACEUTICALS, INC. issued 184,365.8 shares of its Series B Convertible Preferred Stock of preferred stock to affiliate of Invus for $65 per share.

“on January 29, 2026, the Company entered into a Preferred Stock Purchase Agreement with an affiliate of Invus (the “ Preferred Private Placement Purchaser ” and, such agreement, the “ Preferred Purchase Agreement ”), pursuant to which the Company agreed to (i) sell 184,365.8 shares of its Series B Convertible Preferred Stock, par value $0.01 per share (the “ Preferred Stock ”), at a price of $65 per share in a private placement in partial satisfaction of the Invus Entities’ preemptive right under the Certificate of Incorporation”

LEXICON PHARMACEUTICALS, INC. issued 22,400,000 shares of Common Stock of common stock to Artal Participations S.à r.l., Invus Public Equities Advisors, LLC, Invus Global Management, LLC, Invus US Partners LLC, Invus Advisors, L.L.C., Invus Public Equities, L.P., Invus, L.P., Siren, LLC, Ulys, L.L.C. and Mr. Raymond Debbane for $29.12 million.

“and Restated Certificate of Incorporation (the “ Certificate of Incorporation ”). The total purchase price of the Common Stock purchased by the Private Placement Purchasers was $29.12 million. The Common Stock Purchase Agreement incorporates the representations and warranties and covenants made by the Company in the Underwriting Agreement for the benefit of the”

Big Digital Energy, Inc. issued securities.

“MAWSON INFRASTRUCTURE GROUP Inc. (“Mawson” or the “Company”) (Nasdaq: MIGI) today announced that its Board of Directors (the “Board”) unanimously adopted a limited-duration stockholder rights agreement (the “Rights Agreement”) to protect the best interests of Mawson stockholders.”

FiEE, Inc. issued an aggregate of 394,476 shares of the Company's common stock of common stock to certain purchasers named therein (the "Purchasers") for $5.07 per Share.

“the Company agreed to sell and issue to the Purchasers, at the Closing (as defined below), (i) an aggregate of 394,476 shares of the Company’s common stock, $0.01 par value per share (the “Shares”), at an offering price of $5.07 per Share, in a private placement (the “Private Placement”).”

KALA BIO, Inc. issued 2,100,000 shares of Series AAA Preferred Stock of preferred stock to Series AAA Investors for $2.00 per share, for aggregate gross proceeds of $4.2 million.

“an aggregate of 2,100,000 shares of Series AAA Preferred Stock at a price per share of Series AAA Preferred Stock equal to $2.00, for aggregate gross proceeds of $4.2 million.”

APPYEA, INC issued 20,454,545 shares of common stock of warrant to one investor for $450,000.

“with respect to one investor for $450,000, warrants to purchase an additional 20,454,545 shares of common stock, exercisable for a period three years and at per share exercise price $0.026”

APPYEA, INC issued 34,090,908 shares of common stock to four qualified investors for $750,000.

“As of January 27, 2026, AppYea, Inc., a Nevada corporation (the “Company”) accepted subscriptions for $750,000 from four qualified investors in consideration of the issuance, in the aggregate, of 34,090,908 shares of the Company’s common stock”

Regen BioPharma Inc issued 11,111,111 common shares of common stock for $50,000.

“On January 30, 2026 the Company issued 11,111,111 common shares (“Shares”) for consideration consisting of $50,000.”

Regen BioPharma Inc issued 5,302,732 common shares of common stock for $12,000 of principal convertible indebtedness and $1,000 of accrued interest.

“On January 29, 2026 the Company issued 5,302,732 common shares (“Shares”) in satisfaction of $12,000 of principal convertible indebtedness and $1,000 of accrued interest on convertible indebtedness.”

Regen BioPharma Inc issued 5,000,000 common shares of common stock for $11,449 of principal convertible indebtedness and $8,101 of accrued interest.

“On January 15, 2026 the Company issued 5,000,000 common shares (“Shares”) in satisfaction of $11,449 of principal convertible indebtedness and $8,101 of accrued interest on convertible indebtedness.”

Cottonwood Communities, Inc. issued 526,874 shares of preferred stock to accredited investors for $10.00 per share.

“to which it is offering a maximum of $150,000,000 in shares of its Series A Convertible Preferred Stock to accredited investors (the "Private Offering") at a purchase price of $10.00 per share. The exemption is available to the Company because the shares are being offered and sold solely to accredited investors without the use of general solicitation. Sales of”

ESAB Corp issued 1,254,255 shares of Common Stock of common stock to certain institutional investors (the Common Stock Purchasers) for aggregate purchase price of $142,985,070, offered at $114.00 per Common Share.

“on February 2, 2026, the Company offered and agreed to issue and sell 1,254,255 shares of Common Stock (the “Common Shares”) to certain institutional investors (the “Common Stock Purchasers”), pursuant to a common stock purchase agreement (the “Common Stock Purchase Agreement”), for an aggregate purchase price of $142,985,070.”

ESAB Corp issued 175,000 shares of preferred stock to certain investors (the Preferred Stock Purchasers) including one or more entities affiliated with Mitchell Rales and one or more entities affiliated with Steven Rales for aggregate liquidation preference of $175.0 million, offered at $1,000 per Preferred Share.

“On February 2, 2026, the Company offered and agreed to issue and sell 175,000 shares (the “ Preferred Shares ”) of a newly created series of convertible preferred stock, designated as 6.50% Series A Mandatory Convertible Preferred Stock, par value $0.001 per share (the “ Mandatory Convertible Preferred Stock ”), to certain investors (the “ Preferred Stock Purchasers ”), pursuant to a preferred stock purchase agreement (the “ Preferred Stock Purchase Agreement ”), for an aggregate liquidation preference of $175.0 million.”

Newbridge Acquisition Ltd issued 186,250 units of unit to the Sponsor for $10.00 per Private Unit.

“Simultaneously with the closing of the IPO, the Company consummated the private placement (“Private Placement”) with the Sponsor of 186,250 units (the “Private Units”) at a price of $10.00 per Private Unit, generating total proceeds of $1,862,500.”

Advanced Biomed Inc. issued 4,000,000 shares of common stock to certain investors for $0.062 per share for a total purchase price of $248,000.

“On January 28, 2026, Advanced Biomed Inc., a Nevada Corporation (the “Company”), entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain investors (the “Investors”) relating to the issuance and sale of 4,000,000 shares of common stock (the “Purchased Shares”), par value $0.001 per share, of the Company (the “Common Stock”), at $0.062 per share for a total purchase price of $248,000”

Xsolla SPAC 1 issued 400,000 units of unit to Sponsor for $10.00 per Private Unit, generating total proceeds of $4,000,000.

“Simultaneously with the closing of the IPO, the Company consummated a private placement (the “Private Placement”) of an aggregate of 400,000 units (the “Private Units”) to the Sponsor, at a price of $10.00 per Private Unit, generating total proceeds of $4,000,000.”

United Acquisition Corp. I issued 2,333,333 warrants of warrant to Sponsor for $0.75 per Private Placement Warrant.

“On January 30, 2026, simultaneously with the consummation of the Offering, the Company consummated the private placement of 175,000 units to the Sponsor and 100,000 units to the Underwriters (collectively, the "Private Placement Units") at a price of $10.00 per Private Placement Unit, and the Company consummated the private placement of 2,333,333 warrants to the Sponsor (the "Private Placement Warrants") at a price of $0.75 per Private Placement Warrant, generating gross proceeds of $4,500,000 (the "Private Placement").”

United Acquisition Corp. I issued 100,000 units of unit to Underwriters for $10.00 per Private Placement Unit.

“On January 30, 2026, simultaneously with the consummation of the Offering, the Company consummated the private placement of 175,000 units to the Sponsor and 100,000 units to the Underwriters (collectively, the "Private Placement Units") at a price of $10.00 per Private Placement Unit, and the Company consummated the private placement of 2,333,333 warrants to the Sponsor (the "Private Placement Warrants") at a price of $0.75 per Private Placement Warrant, generating gross proceeds of $4,500,000 (the "Private Placement").”

United Acquisition Corp. I issued 175,000 units of unit to Sponsor for $10.00 per Private Placement Unit.

“On January 30, 2026, simultaneously with the consummation of the Offering, the Company consummated the private placement of 175,000 units to the Sponsor and 100,000 units to the Underwriters (collectively, the "Private Placement Units") at a price of $10.00 per Private Placement Unit, and the Company consummated the private placement of 2,333,333 warrants to the Sponsor (the "Private Placement Warrants") at a price of $0.75 per Private Placement Warrant, generating gross proceeds of $4,500,000 (the "Private Placement").”

FIFTH THIRD BANCORP issued preferred stock.

“Fifth Third filed a certificate of amendment (“Certificate of Amendment”) with the Secretary of State of the State of Ohio (the “Ohio Secretary of State”) establishing the respective powers, preferences, privileges and rights of the New Fifth Third Preferred Stock. The Certificate of Amendment became effective on January 31, 2026 at 11:59 pm, Eastern Time.”

Comstock Inc. issued warrant to Titan Partners Group LLC.

“The Company also agreed to issue to the Underwriter, or its designees, warrants (the “Underwriter Warrants”) to purchase 7% of the total number of shares of Common Stock sold in the offering (the “Offering”), including any shares of the Common Stock sold pursuant to the Underwriter’s over-allotment option.”

OptimumBank Holdings, Inc. issued 531,178 newly issued shares of Company common stock of common stock to Michael Blisko for exchanged 65 shares of Company Series B Convertible Preferred Stock.

“On January 27, 2026, OptimumBank Holdings, Inc. (the “Company”) and Michael Blisko entered into, and consummated the transaction contemplated by, an Exchange Agreement. Pursuant to such agreement, Mr. Blisko exchanged 65 shares of Company Series B Convertible Preferred Stock for 531,178 newly issued shares of Company common stock.”

ENvue Medical, Inc. issued exercising $2,500,000 of the Additional Investment Right of preferred stock to Required Holders for the Required Holders agreed to amend the Certificate of Designations to remove the Floor Price in consideration of the holders of the Preferred Stock exercising.

“On January 30, 2026, the Company entered into that certain Amendment Agreement (the " Amendment Agreement ") with the Required Holders (as defined in the Amendment Agreement). Pursuant to the Amendment Agreement, the Required Holders agreed to amend the Certificate of Designations by filing a Certificate of Amendment (the " Certificate of Amendment ") to the Certificate of Designations with the Secretary of State of the State of Delaware to remove the Floor Price (as defined in the Certificate of Designations) in consideration of the holders of the Preferred Stock exercising $2,500,000 of the Additional Investment Right (as such concept is described in the Securities Purchase Agreement by and between the Company and the holders of the Preferred Stock on July 18, 2025, and which such form of Securities Purchase Agreement is filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on July 22, 2025).”

ProMIS Neurosciences Inc. issued Pre-Funded Warrants (the “ Pre-Funded Warrants ”) to purchase 100,000 Common Shares of warrant to PIPE Investors (accredited investors) for the Pre-Funded Warrants have an exercise price of $14.40 per Warrant Share, are immediately exercisable and will expire when exercised in full.

“and 725,221 Common Shares were sold at a price of $12.13 per Common Share to certain affiliates and insiders of the Company. The Common Share Warrants have an exercise price of $14.40, are exercisable immediately and will expire upon the earlier of (i) within 60 days of the Milestone Event (as defined below) or (ii) February 3, 2031. The Pre-Funded Warrants”

ProMIS Neurosciences Inc. issued Common Share purchase warrants (the “ Common Share Warrants ”) to purchase 6,915,296 Common Shares of warrant to PIPE Investors (accredited investors) for the Common Share Warrants have an exercise price of $14.40, are exercisable immediately and will expire ... up to an additional approximately $100 million in gr.

“and 725,221 Common Shares were sold at a price of $12.13 per Common Share to certain affiliates and insiders of the Company. The Common Share Warrants have an exercise price of $14.40, are exercisable immediately and will expire upon the earlier of (i) within 60 days of the Milestone Event (as defined below) or (ii) February 3, 2031. The Pre-Funded Warrants”

ProMIS Neurosciences Inc. issued 6,090,075 Common Shares were sold at a price of $10.77 per Common Share, 100,000 Pre-Funded Warrants were sold at a price of $10.77 less an exercise price $0.00 of common stock to PIPE Investors (accredited investors) for $75 million in aggregate gross proceeds.

“On January 29, 2026, ProMIS Neurosciences Inc. (the “ Company ”) entered into a Securities Purchase Agreement (the “ Securities Purchase Agreement ”) with selected investors that qualify as “accredited investors” (the “ PIPE Investors ”), as defined in Rule 501(a) of Regulation D promulgated under the United States Securities Act of 1933, as amended (the “ Securities Act ”), for the purpose of raising approximately $75 million in aggregate gross proceeds for the Company (the “ Offering ”) before deducting placement agent fees and other expenses payable by the Company.”

INVO Fertility, Inc. issued 9,467,456 shares of Common Stock of warrant to institutional investor for The holder agreed to exercise the Existing Warrants for cash at a reduced exercise price of $1.59 per share, resulting in gross proceeds of approximately $7.5 m.

“(the “SEC”) on December 29, 2025. Pursuant to the Inducement Letter Agreement, the Holder agreed to exercise the Existing Warrants for cash at a reduced exercise price of $1.59 per share in consideration for the Company’s agreement to issue new unregistered warrants to purchase up to an aggregate of 9,467,456 shares of Common Stock at an exercise price”

Nuwellis, Inc. issued January Inducement Warrants of warrant to certain investors.

“the Company offered and sold the Securities and January Inducement Warrants in reliance on Section 4(a)(2) of the Securities Act and/or Rule 506 promulgated thereunder”

Nuwellis, Inc. issued 1,989,074 Common Warrant Shares of common stock to a certain institutional accredited investor for combined purchase price of $3.09.

“of Common Stock (the “ Common Warrant Shares ” and together with the Pre-Funded Warrant Shares and the Pre-Funded Warrants, the “ Securities ”) for a combined purchase price of $3.09. Under the terms of the Pre-Funded Warrants and Common Warrants, a holder will not be entitled to exercise any portion of any Pre-Funded Warrant or Common Warrant, if, upon”

Nuwellis, Inc. issued 994,537 Pre-Funded Warrant Shares of common stock to a certain institutional accredited investor for combined purchase price of $3.09.

“of Common Stock (the “ Common Warrant Shares ” and together with the Pre-Funded Warrant Shares and the Pre-Funded Warrants, the “ Securities ”) for a combined purchase price of $3.09. Under the terms of the Pre-Funded Warrants and Common Warrants, a holder will not be entitled to exercise any portion of any Pre-Funded Warrant or Common Warrant, if, upon”

Nuwellis, Inc. issued 1,989,074 common warrants of warrant to a certain institutional accredited investor for combined purchase price of $3.09.

“of Common Stock (the “ Common Warrant Shares ” and together with the Pre-Funded Warrant Shares and the Pre-Funded Warrants, the “ Securities ”) for a combined purchase price of $3.09. Under the terms of the Pre-Funded Warrants and Common Warrants, a holder will not be entitled to exercise any portion of any Pre-Funded Warrant or Common Warrant, if, upon”

Nuwellis, Inc. issued 994,537 pre-funded common stock purchase warrants of warrant to a certain institutional accredited investor for combined purchase price of $3.09.

“of Common Stock (the “ Common Warrant Shares ” and together with the Pre-Funded Warrant Shares and the Pre-Funded Warrants, the “ Securities ”) for a combined purchase price of $3.09. Under the terms of the Pre-Funded Warrants and Common Warrants, a holder will not be entitled to exercise any portion of any Pre-Funded Warrant or Common Warrant, if, upon”

SPLASH BEVERAGE GROUP, INC. issued a total of 360,648 shares of common stock of common stock to convertible note holders for conversion of a total of $200,000 of convertible notes.

“On October 27, 2025, November 25, 2025, and December 11, 2025, the Company issued a total of 360,648 shares of common stock upon the conversion of a total of $200,000 of convertible notes.”

SPLASH BEVERAGE GROUP, INC. issued 145,029 shares of common stock of common stock to ELOC investors for total gross proceeds of $98,170.

“On January 27, 2026, Splash Beverage Group, Inc. (the “Company”) sold a total of 145,029 shares of common stock for total gross proceeds of $98,170 under that certain Common Stock Purchase Agreement and Registration Rights Agreement dated September 19, 2025 (collectively, the “ELOC Agreement”), which ELOC Agreement was previously disclosed on the Company’s Current Report on Form 8-K filed on September 25, 2025.”

AI Era Corp. issued convertible note to Crom Structured Opportunities Fund I, LP for $154,500 principal amount; $150,000 cash proceeds.

“On January 28, 2026, the Company entered into a Securities Purchase Agreement (the “Crom SPA” and, together with the Monroe SPA, the “SPAs”) with Crom Structured Opportunities Fund I, LP (“Crom”), pursuant to which the Company issued to Crom a convertible promissory note in the principal amount of $154,500 (the “Crom Note” and, together with the Monroe Note, the “Notes”) for cash proceeds of $150,000 (reflecting $4,500 original issue discount).”

AI Era Corp. issued convertible note to Monroe Street Capital Partners LP for $154,500 principal amount; $150,000 cash proceeds.

“On January 27, 2026, AI Era Corp. (the “Company”) entered into a Securities Purchase Agreement (the “Monroe SPA”) with Monroe Street Capital Partners LP (“Monroe”), pursuant to which the Company issued to Monroe a convertible promissory note in the principal amount of $154,500 (the “Monroe Note”) for cash proceeds of $150,000 (reflecting $4,500 original issue discount).”

Silver Point Specialty Lending Fund issued 357,654 of common stock to existing shareholders for $10,000,000 aggregate offering price, $27.96 per Share.

“As of January 2, 2026, Silver Point Specialty Lending Fund (the “Fund”) issued and sold 357,654 of its unregistered common shares of beneficial interest, par value $0.001 per share (the “Shares”), for an aggregate offering price of $10,000,000, reflecting a purchase price of $27.96 per Share (with the final number of Shares being determined on January 26, 2026).”

International Land Alliance Inc. issued 5,337,316 shares of common stock of warrant to Mast Hill Fund L.P..

“b. The New Warrant issued January 29, 2026, pursuant to which Mast Hill may purchase 5,337,316 shares of Company common stock for a term of 10 years from issuance, and exercisable by cash or cashless option, at an initial exercise price equal to $0.6695 per share”

Arrive AI Inc. issued common stock to Streeterville Capital, LLC for $10,000,000 to the Company.

“Under the Pre-Paid Purchase No. 4, the Investor paid $10,000,000 to the Company, representing the purchase price for an unsecured promissory note with an original principal balance of $10,800,000, which included an $800,000 original issue discount.”